PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27793909-3 2016 MATERIALS AND METHODS: The anti-malarial drugs chloroquine (CHL), mefloquine (MEF) and primaquine (PRI) have been shown to increase sensitization in drug-resistant KBV20C cells via P-gp inhibition. Mefloquine 66-76 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 17015054-0 2006 MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Mefloquine 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 21302473-0 2010 [Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis]. Mefloquine 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 21302473-5 2010 Genetic studies have found polymorphism at the MDR1 gene with genotypes 3435TT and 2677TT which underlie high levels of mefloquine in the brain. Mefloquine 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 27045516-10 2016 Mefloquine was shown to be a P-gp inhibitor affecting our P-gp substrate, Rhodamine 123, although none of the other drugs impacted upon rhodamine123 transport rates. Mefloquine 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 27045516-10 2016 Mefloquine was shown to be a P-gp inhibitor affecting our P-gp substrate, Rhodamine 123, although none of the other drugs impacted upon rhodamine123 transport rates. Mefloquine 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 27045516-11 2016 In conclusion, mefloquine is a P-gp inhibitor and methylene blue is a partial substrate; methylene blue may have increased absorption if co-administered with such P-gp inhibitors. Mefloquine 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 27045516-11 2016 In conclusion, mefloquine is a P-gp inhibitor and methylene blue is a partial substrate; methylene blue may have increased absorption if co-administered with such P-gp inhibitors. Mefloquine 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 27045516-12 2016 An upregulation of P-gp was observed when artemisone and dihydroartemisinin were co-incubated with mefloquine and amodiaquine. Mefloquine 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 24874696-9 2014 More large studies in other ethnic groups including polymorphism studies for the gene encoding P-glycoprotein (ABCB1/MDR1) and taking into account various underlying conditions with secondary immunosuppression should be carried out to investigate whether mefloquine is effective for treating PML. Mefloquine 255-265 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 24284282-0 2013 Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition. Mefloquine 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 17015054-2 2006 We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein. Mefloquine 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 17015054-2 2006 We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein. Mefloquine 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 17015054-2 2006 We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein. Mefloquine 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 158-172 17015054-9 2006 CONCLUSION: In this study the MDR1 1236TT, 2677TT, and 3435TT genotypes, along with the 1236-2677-3435 TTT haplotype, were associated with neuropsychiatric adverse effects of mefloquine in women. Mefloquine 175-185 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 17015054-10 2006 MDR1 polymorphisms may play an important role in predicting the occurrence of neuropsychiatric adverse effects of mefloquine, particularly in female travelers. Mefloquine 114-124 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 11683248-0 2001 The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. Mefloquine 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 11683248-0 2001 The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. Mefloquine 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 16843615-2 2006 PRESENTATION OF THE HYPOTHESIS: Psychosis is caused by interactions with other drugs or by pharmacogenetic vulnerabilities that cause heightened responses to chloroquine or mefloquine alone, mediated through dopamine, acetylcholine, serotonin, P-glycoprotein, inhibited cortical activity, deranged calcium homeostasis, and impaired synaptogenesis. Mefloquine 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 244-258 11031728-5 2000 Our results indicate that mefloquine inhibits the P-glycoprotein pump-efflux activity in a dose-related manner. Mefloquine 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 11031728-6 2000 Moreover, mefloquine reduces the expression of the immunoreactive P-glycoprotein in K562/DXR cells as evaluated by cytofluorimetric assay. Mefloquine 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 11031728-7 2000 Taken together, the results indicate that mefloquine reverses the multidrug-resistance phenotype through direct interaction with P-glycoprotein. Mefloquine 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 129-143 8937469-0 1996 Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Mefloquine 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 8937469-0 1996 Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Mefloquine 81-91 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 8937469-2 1996 Mefloquine, a quinolinemethanol antimalarial drug, was shown to inhibit the labelling of P-glycoprotein with an efficiency similar to that for verapamil, a known chemosensitizer. Mefloquine 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 8937469-4 1996 Mefloquine also inhibited the functional activity of P-glycoprotein. Mefloquine 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 8937469-6 1996 The ability of mefloquine to inhibit P-glycoprotein function may be involved in the neurotoxic side-effects occasionally associated with the use of mefloquine as an antimalarial drug. Mefloquine 15-25 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 8937469-6 1996 The ability of mefloquine to inhibit P-glycoprotein function may be involved in the neurotoxic side-effects occasionally associated with the use of mefloquine as an antimalarial drug. Mefloquine 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 37-51